As of November 6, 2026, CNS Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: CNSP); its largest reported holder is Ikarian Capital, LLC, with 9.9% on Schedule 13G/A of August 14, 2026, then Stonepine Capital Management, LLC (9.9%). The largest insider holding is Faith Charles, a director, with 7,100 shares (0.49% of shares outstanding), per Form 4 of May 20, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in CNS Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is CNS Pharmaceuticals, Inc. a real, registered company?
- CNS Pharmaceuticals, Inc. files with the SEC under CIK 1729427 (its SEC filings).
- Its shares are listed under the ticker CNSP on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in Houston, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CNS Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Ikarian Capital, LLC (filed 2026-08-14).
Who are CNS Pharmaceuticals, Inc.'s owners and officers?
CNS Pharmaceuticals, Inc.: incorporated in Nevada; business address in Houston, Texas; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-05-19)
- : Executive Officer (Form D, 2026-05-19)
- : Director (Form D, 2026-05-19)
- : Director (Form D, 2026-05-19)
- : Director (Form D, 2026-05-19)
- : Director (Form D, 2026-05-19)
- : Director (Form D, 2026-05-19)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Ikarian Capital, LLC | 9.9% |
| Schedule 13G/A, 2026-05-15 | Stonepine Capital Management, LLC | 9.9% |
| Schedule 13G, 2026-04-17 | Ikarian Capital, LLC | 5.7% |
| Schedule 13G/A, 2026-02-13 | Stonepine Capital Management, LLC | 7.9% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2025-11-04 | Stonepine Capital Management, LLC | 5.6% |
| Schedule 13G, 2025-08-14 | Armistice Capital, LLC | 9.99% |
Questions about who owns CNS Pharmaceuticals, Inc.
Who owns CNS Pharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of CNS Pharmaceuticals, Inc.: Ikarian Capital, LLC (9.9%, Schedule 13G/A, filed 2026-08-14) and Stonepine Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of CNS Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of CNS Pharmaceuticals, Inc. on this page are Ikarian Capital, LLC (9.9%) and Stonepine Capital Management, LLC (9.9%).
When did Ikarian Capital, LLC buy into CNS Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ikarian Capital, LLC on this page is the Schedule 13G, filed 2026-04-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on CNS Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CNS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CNS Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own CNS Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 7,100 shares (0.49% of shares outstanding) (Form 4, 2026-05-20).
- , the chief executive and president: 4,750 shares (0.33% of shares outstanding) (Form 4, 2026-08-18).
- , a director: 2,000 shares (0.14% of shares outstanding) (Form 4, 2026-08-18).
Shares outstanding: 1,461,449 as of 2026-08-11, from the company's latest SEC cover page.
How much has CNS Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-05-19 | $22.52M | $22.52M |
Latest IPO step: CNS Pharmaceuticals, Inc. filed its final IPO prospectus, ticker CNSP (424B4, 2025-05-14).
IPO filings: 424B4, 2025-05-14, S-1/A, 2025-05-12, S-1, 2025-04-14, RW, 2024-07-31, S-1/A, 2024-07-19; ticker CNSP on Nasdaq Capital Market.
Keep reading
More on CNS Pharmaceuticals, Inc. and the records around it.
CNS Pharmaceuticals, Inc. elsewhere on the record
- Form D filing May 2026
Companies that share a holder
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cns-pharmaceuticals